Update: 17.12.2021
Last week: 49th week 2021 (06.12.2021 - 12.12.2021)
Last full month: Nov 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 1 768 | 2.3% | 45.9% | -0.9 | 791 755 | 4.5% | 76.3% | -0.4 |
| MoM | 7 959 | -19.1% | 47.1% | -5.7 | 3 472 255 | -18.8% | 76.7% | -3.8 |
| YTD | 112 471 | -23.9% | 56.2% | -5.6 | 43 390 023 | 0.2% | 80.5% | -0.1 |
| MAT | 121 371 | -23.3% | 56.5% | -5.2 | 46 343 223 | 0.3% | 80.6% | 0.1 |
| CAPSICAM | ||||||||
| WoW | 24 382 | 6.1% | 4.0% | 0.1 | 9 866 486 | 5.9% | 4.3% | 0.1 |
| MoM | 95 769 | -2.9% | 3.5% | 0.3 | 38 687 899 | -3.0% | 3.7% | 0.3 |
| YTD | 993 363 | -19.6% | 3.1% | -0.3 | 409 710 962 | -5.3% | 3.5% | -0.2 |
| MAT | 1 086 476 | -18.6% | 3.2% | -0.3 | 448 526 495 | -3.2% | 3.5% | -0.1 |
| MILDRONATE | ||||||||
| WoW | 98 427 | 1.8% | 12.2% | 0 | 38 243 274 | 2.1% | 17.3% | -0.1 |
| MoM | 452 608 | -4.7% | 12.5% | -0.2 | 173 520 666 | -5.0% | 17.3% | 0.2 |
| YTD | 4 524 224 | 14.6% | 9.3% | 1.5 | 1 827 780 627 | 21.0% | 14.1% | 2.4 |
| MAT | 4 859 634 | 15.9% | 9.2% | 1.4 | 1 968 908 148 | 23.1% | 14.1% | 2.3 |
| SULFARGIN | ||||||||
| WoW | 3 616 | 10.8% | 1.0% | 0 | 1 763 039 | 10.6% | 1.5% | 0 |
| MoM | 12 818 | -5.2% | 0.9% | 0 | 6 444 451 | -5.0% | 1.3% | 0 |
| YTD | 151 703 | -23.2% | 0.8% | -0.2 | 73 770 299 | -9.7% | 1.2% | -0.1 |
| MAT | 163 500 | -21.2% | 0.8% | -0.2 | 79 238 937 | -7.3% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 32 409 | 10.3% | 5.3% | 0.3 | 12 677 276 | 11.0% | 5.5% | 0.4 |
| MoM | 141 907 | -0.9% | 5.2% | 0.5 | 54 642 364 | 1.6% | 5.3% | 0.6 |
| YTD | 1 152 062 | -13.7% | 3.6% | -0.1 | 434 672 570 | -3.7% | 3.7% | -0.1 |
| MAT | 1 242 632 | -12.9% | 3.6% | -0.1 | 469 739 581 | -1.8% | 3.7% | -0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 1 768 | 2.3% | 45.9% | -0.9 | 791 755 | 4.5% | 76.3% | -0.4 |
| CAPSICAM | 24 382 | 6.1% | 4.0% | 0.1 | 9 866 486 | 5.9% | 4.3% | 0.1 |
| MILDRONATE | 98 427 | 1.8% | 12.2% | 0 | 38 243 274 | 2.1% | 17.3% | -0.1 |
| SULFARGIN | 3 616 | 10.8% | 1.0% | 0 | 1 763 039 | 10.6% | 1.5% | 0 |
| VIPROSAL | 32 409 | 10.3% | 5.3% | 0.3 | 12 677 276 | 11.0% | 5.5% | 0.4 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 959 | -19.1% | 47.1% | -5.7 | 3 472 255 | -18.8% | 76.7% | -3.8 |
| CAPSICAM | 95 769 | -2.9% | 3.5% | 0.3 | 38 687 899 | -3.0% | 3.7% | 0.3 |
| MILDRONATE | 452 608 | -4.7% | 12.5% | -0.2 | 173 520 666 | -5.0% | 17.3% | 0.2 |
| SULFARGIN | 12 818 | -5.2% | 0.9% | 0 | 6 444 451 | -5.0% | 1.3% | 0 |
| VIPROSAL | 141 907 | -0.9% | 5.2% | 0.5 | 54 642 364 | 1.6% | 5.3% | 0.6 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 112 471 | -23.9% | 56.2% | -5.6 | 43 390 023 | 0.2% | 80.5% | -0.1 |
| CAPSICAM | 993 363 | -19.6% | 3.1% | -0.3 | 409 710 962 | -5.3% | 3.5% | -0.2 |
| MILDRONATE | 4 524 224 | 14.6% | 9.3% | 1.5 | 1 827 780 627 | 21.0% | 14.1% | 2.4 |
| SULFARGIN | 151 703 | -23.2% | 0.8% | -0.2 | 73 770 299 | -9.7% | 1.2% | -0.1 |
| VIPROSAL | 1 152 062 | -13.7% | 3.6% | -0.1 | 434 672 570 | -3.7% | 3.7% | -0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 121 371 | -23.3% | 56.5% | -5.2 | 46 343 223 | 0.3% | 80.6% | 0.1 |
| CAPSICAM | 1 086 476 | -18.6% | 3.2% | -0.3 | 448 526 495 | -3.2% | 3.5% | -0.1 |
| MILDRONATE | 4 859 634 | 15.9% | 9.2% | 1.4 | 1 968 908 148 | 23.1% | 14.1% | 2.3 |
| SULFARGIN | 163 500 | -21.2% | 0.8% | -0.2 | 79 238 937 | -7.3% | 1.2% | -0.1 |
| VIPROSAL | 1 242 632 | -12.9% | 3.6% | -0.1 | 469 739 581 | -1.8% | 3.7% | -0.1 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs